Citadel Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-38,900
| Closed | -$8.19K | – | 15485 |
|
|
2023
Q2 | $8.19K | Sell |
38,900
-1,000
| -3% | -$174 | ﹤0.01% | 13334 |
|
|
2023
Q1 | $6.38K | Sell |
39,900
-16,200
| -29% | -$7.19K | ﹤0.01% | 13814 |
|
|
2022
Q4 | $31.1K | Sell |
56,100
-9,300
| -14% | -$7.91K | ﹤0.01% | 12702 |
|
|
2022
Q3 | $78K | Sell |
65,400
-3,400
| -5% | -$3.67K | ﹤0.01% | 11299 |
|
|
2022
Q2 | $44K | Buy |
68,800
+12,000
| +21% | +$9.21K | ﹤0.01% | 12016 |
|
|
2022
Q1 | $65K | Sell |
56,800
-9,900
| -15% | -$11.8K | ﹤0.01% | 12625 |
|
|
2021
Q4 | $150K | Sell |
66,700
-54,500
| -45% | -$137K | ﹤0.01% | 12261 |
|
|
2021
Q3 | $415K | Sell |
121,200
-9,400
| -7% | -$29K | ﹤0.01% | 10329 |
|
|
2021
Q2 | $390K | Sell |
130,600
-3,800
| -3% | -$12K | ﹤0.01% | 10634 |
|
|
2021
Q1 | $434K | Buy |
134,400
+116,400
| +647% | +$388K | ﹤0.01% | 10005 |
|
|
2020
Q4 | $38K | Buy |
+18,000
| New | +$29.7K | ﹤0.01% | 10663 |
|
|
2019
Q2 | – | Sell |
-10,300
| Closed | -$19K | – | 10046 |
|
|
2019
Q1 | $19K | Sell |
10,300
-2,000
| -16% | -$2.93K | ﹤0.01% | 9073 |
|
|
2018
Q4 | $15K | Sell |
12,300
-30,600
| -71% | -$55K | ﹤0.01% | 8845 |
|
|
2018
Q3 | $116K | Sell |
42,900
-16,000
| -27% | -$33.1K | ﹤0.01% | 8516 |
|
|
2018
Q2 | $112K | Buy |
58,900
+36,000
| +157% | +$72.7K | ﹤0.01% | 8189 |
|
|
2018
Q1 | $48K | Buy |
22,900
+7,900
| +53% | +$16.9K | ﹤0.01% | 7935 |
|
|
2017
Q4 | $30K | Buy |
+15,000
| New | +$31.1K | ﹤0.01% | 7769 |
|
|
2016
Q3 | – | Sell |
-10,600
| Closed | -$14K | – | 7923 |
|
|
2016
Q2 | $14K | Buy |
+10,600
| New | +$49.6K | ﹤0.01% | 6699 |
|
|
2015
Q4 | – | Sell |
-10,800
| Closed | -$91K | – | 9341 |
|
|
2015
Q3 | $91K | Buy |
10,800
+700
| +7% | +$6.46K | ﹤0.01% | 7048 |
|
|
2015
Q2 | $111K | Sell |
10,100
-6,900
| -41% | -$88.6K | ﹤0.01% | 6983 |
|
|
2015
Q1 | $238K | Sell |
17,000
-6,700
| -28% | -$102K | ﹤0.01% | 5964 |
|
|
2014
Q4 | $400K | Sell |
23,700
-19,100
| -45% | -$278K | ﹤0.01% | 5038 |
|
|
2014
Q3 | $574K | Buy |
42,800
+33,300
| +351% | +$397K | ﹤0.01% | 4428 |
|
|
2014
Q2 | $121K | Sell |
9,500
-6,600
| -41% | -$68.8K | ﹤0.01% | 6080 |
|
|
2014
Q1 | $191K | Sell |
16,100
-8,800
| -35% | -$118K | ﹤0.01% | 5565 |
|
|
2013
Q4 | $344K | Buy |
24,900
+4,800
| +24% | +$67.8K | ﹤0.01% | 4468 |
|
|
2013
Q3 | $351K | Buy |
20,100
+7,200
| +56% | +$138K | ﹤0.01% | 4193 |
|
|
2013
Q2 | $210K | Buy |
+12,900
| New | +$399K | ﹤0.01% | 4628 |
|
Other funds holding INFI
Citadel Advisors's INFI Position: Q2 2023 in Review
Citadel Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2023, closing a stake of 393,296 shares — an estimated $68.3K sold.
Citadel Advisors first reported a position in INFI in Q2 2013 and held it in 28 quarters. The position peaked at $7.57M in Q4 2014. 45 funds tracked by Wall St. Rank hold INFI as of Q2 2023.
- Citadel Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 393,296 Infinity Pharmaceuticals, Inc. shares in Q2 2023, an estimated $68.3K.
- Citadel Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
- Citadel Advisors's Infinity Pharmaceuticals, Inc. position peaked at $7.57M in Q4 2014.
- 45 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.